GLP-1 Science
GLP-1 and Smoking Cessation Research
Emerging research suggests semaglutide may reduce tobacco use, an unexpected finding still being actively studied. Here...
Mazdutide is the first of the new generation of dual agonists to actually reach patients. China approved it in June 2025 for chronic weight management in adults with obesity or overweight.
That makes it worth understanding for a reason beyond the drug itself. It shows that the assumption that new obesity medicines always launch in the United States first is no longer reliable.
What mazdutide is
Mazdutide is a once-weekly injection developed by Innovent Biologics, a Chinese pharmaceutical company, originally licensed from Eli Lilly.
It is a dual agonist activating GLP-1 and glucagon receptors. This is the same receptor pairing survodutide uses, and a different one from tirzepatide, which pairs GLP-1 with GIP.
How the mechanism works
GLP-1 (glucagon-like peptide-1) is the gut hormone released after eating. Activating its receptor slows stomach emptying, signals fullness to your brain and reduces appetite.
Glucagon receptor activation does something the GLP-1 side does not. It increases energy expenditure, meaning your body burns more calories at rest, and it promotes breakdown of fat stored in the liver.
The combination therefore works on both sides of the energy equation. Less in, more out.
The same principle drives retatrutide, which adds GIP to these two receptors. Its phase 2 trial, published in the New England Journal of Medicine, demonstrated how much this receptor-stacking approach can achieve.
The difficulty with any glucagon-containing drug is balance. Glucagon raises blood sugar while GLP-1 lowers it, so the ratio between the two actions has to be precisely tuned. Getting it wrong produces either poor glucose control or insufficient weight effect.
Why the China approval matters
For decades, the pattern for new medicines has been predictable. Approval in the United States or Europe first, then other developed markets, then eventually elsewhere. Countries like Pakistan sat near the end of that queue.
Mazdutide broke the sequence. It was approved in China before any Western regulator considered it.
Two things drove this. Innovent is a Chinese company that ran its pivotal trials in Chinese populations and filed with China's regulator first. And China's obesity burden has grown fast enough to create strong domestic regulatory motivation.
There is a further point worth noting. Drug response is not uniform across populations. Trials conducted in Chinese participants generate data more directly relevant to East Asian patients than trials conducted primarily in North America and Europe.
The same argument applies to South Asia, where almost no obesity drug trials have been conducted. Body composition, fat distribution and metabolic risk at a given BMI all differ meaningfully in South Asian populations, and the evidence base largely does not reflect that.
Where it is available
Approved: China, since June 2025, for chronic weight management in adults with obesity or overweight.
Not approved: The United States, the European Union, the United Kingdom, and Pakistan. Mazdutide remains in late-stage development outside China, with no confirmed filing or approval timeline for Western markets.
Approval in one country creates no legal route to obtain a drug in another. A medicine approved in China cannot be legitimately prescribed or sold in Pakistan.
The counterfeit consideration
Mazdutide's situation creates a specific risk worth naming.
Because it is genuinely approved somewhere, sellers can point to a real approval to lend credibility to an unverified product. That is more persuasive than marketing a drug approved nowhere, such as retatrutide.
An approval in China does not verify the pen in an unregulated seller's hand in Karachi. Whether that product is authentic Innovent mazdutide, correctly stored through transit, or the substance it claims to be at all, is unknown and unknowable to the buyer.
The reasoning that a drug is approved somewhere and therefore what is being sold must be real does not hold. Supply chain is the whole question.
Side effects
The reported profile matches the class. Nausea, vomiting, diarrhoea and constipation are common, dose-related, and worst during escalation.
Glucagon receptor activation adds increased heart rate and requires attention to blood sugar effects, particularly in people with diabetes.
Long-term safety data outside Chinese populations is limited simply because the drug has not been widely used elsewhere.
What this means for Pakistan
Mazdutide is not available in Pakistan through any legitimate channel and there is no indication that will change soon.
The wider lesson is more useful than the drug itself. Pakistan has never had registered access to semaglutide or tirzepatide, despite both being approved in major markets for years. Waiting for the newest drug to arrive is not a strategy, because the ones approved years ago have not arrived either.
That leaves the route most people here take instead, which is working with what is physician-reviewed and obtainable locally. METASLIM™ is a physician-reviewed GLP-1 sublingual supplement with a physician reviewing each order before dispatch. It is not a dual agonist and not a pharmaceutical peptide, so trial figures from mazdutide or any other injectable have no application to it. Its relevance is that it exists here with consistent physician oversight, which no imported unverified pen does.
See the full range of medical weight loss options available locally. Our complete GLP-1 medication list covers every approved drug worldwide, and survodutide covers the other GLP-1 and glucagon dual agonist.
The summary
Mazdutide is a GLP-1 and glucagon dual agonist approved in China since June 2025 for chronic weight management. It is the first of this new generation to reach any market.
It is not approved in the United States, Europe or Pakistan, and remains in late-stage development elsewhere.
Its most significant feature may be the precedent. New obesity drugs no longer necessarily launch in Western markets first, and trials run in Asian populations generate data that better reflects those patients.
For Pakistan specifically, it changes nothing about what is obtainable today.
See the program and order with cash on delivery for what is actually available here.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.